Development of small molecule inhibitors of RBM46 as novel male contraceptives
Active Grant Awarded Last action
- Award ID
- R33HD114223
- Recipient
-
The University Of Texas At San Antonio UEI U44ZMVYU52U6 Part of University Of Texas System
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $791,682
Award facts
- Assistance listing
- 93.865 Child Health and Human Development Extramural Research
- Completion date 26% complete
- Place of performance
- San Antonio, TX 78249, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services' National Institutes of Health, through the National Institute of Child Health and Human Development, awarded The University of Texas at San Antonio $791,682 on February 11, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865). The award, Grant R33HD114223, funds development of small molecule inhibitors of RBM46 as novel male contraceptives. The approach is to develop drugs that target RBM46 degradation as an oral, non-hormonal male contraceptive, based on the observation that RBM46 knockout mice are sterile with no other phenotype. Place of performance is San Antonio, Texas 78249, and the ultimate completion date is January 31, 2029.
Three sub-recipients share the work. The Texas Biomedical Research Institute, doing business as the Southwest Foundation for Biomedical Research, is conducting pharmacokinetic testing of two drugs at three doses each, along with efficacy and safety studies of reversible sterility in male marmosets. Its subaward is dated August 21, 2026. The University of Texas Health Science Center at San Antonio, under a subaward dated June 12, 2026, is performing computer-aided drug discovery and high-throughput screening of RBM46 small molecule degraders, validating the resulting hits, and guiding PROTAC development with the CIDD Medicinal Chemistry Core. East Carolina University, through the Brody School of Medicine under a subaward dated June 5, 2026, is performing in vitro and in vivo mouse experiments, including validation that PROTAC molecules degrade more than 80% of endogenous protein in male germ cells.
Description
- Abstract
- Development of novel contraceptive strategies is central to the mission of the contraceptive research branch of the nichd. This goal is driven by a global need for effective contraceptive methods to address: 1) the glut of unintended pregnancies (~45% of US pregnancies in 2011); 2) the high rate of elective abortion (1.15M unintended pregnancies ended in abortion in 2011 in the US); and 3) the high risk of maternal mortality (~830 women/day worldwide DIE due to pregnancy or childbirth complications). In a search for novel male contraceptive drug targets, we identified RBM46, which is a germ cell-specific RNA binding protein expressed by germ cells on the basement membrane of seminiferous tubules (outside the blood-testis-barrier), and is essential for spermatogenesis. Indeed, RBM46 knockout mice are sterile and have no other phenotype, raising the distinct possibility that targeting RBM46 could lead to safe and effective male contraception by blocking spermatogenesis at the differentiating spermatogonial stage. Thus, we propose to develop drugs that target degradation of RBM46 as a means of oral, non-hormonal male contraception, which will significantly advance additional safe and reversible options for male contraception towards the clinic. Specifically, we will combine: 1) exceptional expertise in drug screening and development at utsa and UT health SAN antonio; 2) leading expertise in male reproduction, spermatogenesis, and infertility at utsa and ECU; 3) close proximity to one of two NIH-designated marmoset breeding colonies, maintained at the southwest national primate research center; 4) growing and ongoing experience collecting and assessing marmoset sperm; 5) published experience in the use of cutting- edge single-cell genomics to assess normality of spermatogenic cell types; and 6) documented expertise with spermatogonial stem cell (SSC) transplantation. In aim 1, we will identify small molecules that bind RBM46 and could be used to develop protacs. In aim 2, we will produce initial RBM46 protacs and validate that they degrade the protein in vitro. In aim 3, we will use medicinal chemistry to optimize the drug-like characteristics of top validated RBM46 protacs. In aims 4 and 5, we will determine whether optimized RBM46 protacs induce reversible contraception in vivo using mice and marmosets, respectively. Together, these aims are designed to advance RBM46 degradation as a novel strategy to achieve reversible, non-hormonal male contraception and provide key results to justify further preclinical investigation and eventual commercialization.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $46,383 | |
| Amendment | $2,183 | |
| Amendment | $27,603 | |
| Original award | $715,513 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Texas Biomedical Research Institute | $156,689 | |
| The University Of Texas Health Science Center At San Antonio | $142,846 | |
| East Carolina University | $133,113 |
Quick answers
Who received award R33HD114223?
R33HD114223 was awarded to The University Of Texas At San Antonio by National Institute of Child Health and Human Development (National Institutes of Health) on February 11, 2026.
How much is award R33HD114223 worth?
$791,682 has been obligated on R33HD114223.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award